Myungmoon Pharmaceutical Rises 6.68% Amid Deworming Drug (Fenbendazole, etc.) Theme Uptrend

On the 15th, the deworming drug theme (including Fenbendazole) rose by 3.24% compared to the previous day, showing strength, while Myungmoon Pharmaceutical, which is attracting attention as a related stock, surged by 6.68% compared to the previous day. Myungmoon Pharmaceutical is known as a comprehensive pharmaceutical company focusing on prescription drugs.

[Graph] Major stock price changes in the deworming drug theme (including Fenbendazole)



According to preliminary data compiled at 10:56, foreigners have sold -29,000 shares of Myungmoon Pharmaceutical, indicating a large net selling by foreign investors.

[Table] Net trading volume of foreigners and institutions (unit: 10,000 shares)



According to the analysis by Thinkpool Robo Algorithm RASSI, Myungmoon Pharmaceutical’s quant financial score is 7.36 points, which is lower in stability, profitability, and growth compared to the average of other stocks related to the deworming drug theme (including Fenbendazole). This can be interpreted as Myungmoon Pharmaceutical having relatively low investment attractiveness compared to other stocks from a financial perspective. On the other hand, Aliko Pharmaceutical ranked first in quant financial ranking with higher growth, stability, and profitability scores compared to the average of other stocks.

[Table] Top stocks by financial score within the theme


※ The quant financial score is the result of the Robo Algorithm’s analysis based on each company’s sales growth rate, equity growth rate, debt ratio, current ratio, ROA, ROE, etc.

※ This article was generated in real time by an article automatic generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.

This content was produced with the assistance of AI translation services.